Malte Peters

Education and Early Career

Malte Peters is a prominent figure in the pharmaceutical and biotech industries, with a career spanning over two decades. His journey began with a foundational education in medicine. He earned his Medical Doctor (MD) degree from Freie Universität Berlin, where he studied from January 1986 to January 1990. This solid educational background paved the way for his impressive career in clinical development and research.

Career Progression

Peters has held numerous key positions throughout his career. He started as the Global Head of Translational Medicine at Merck KGaA. Soon after, he moved to Micromet AG, where he served as the Medical Director of Oncology from January 2003 to June 2004. His career continued to ascend as he took on roles with increasing responsibility and influence.

Notable Contributions at Major Organizations

At Novartis, Peters made significant contributions as the Vice President of Early Development, a position he held from June 2004 to May 2015. He later joined Sandoz as the Global Head of Clinical Development Biopharmaceuticals, serving from June 2015 to February 2017. His expertise in clinical trials, biopharmaceuticals, and oncology significantly advanced the missions of these organizations.

Leadership at MorphoSys

In March 2017, Peters transitioned to MorphoSys, a leading biotechnology company. He initially served as the Chief Development Officer before being promoted to Chief Research and Development Officer in March 2020. Under his leadership, the company made substantial strides in developing treatments for cancer and autoimmune diseases. He remained with MorphoSys until December 2022, leaving behind a legacy of innovation and progress.

Board Memberships and Future Roles

In addition to his roles in pharmaceutical development, Peters has served on several supervisory and advisory boards.

• Since October 2018, he has been a Board Member at Tango Therapeutics, contributing his expertise to the biotech community.
• He joined HOOKIPA Pharma Inc. as a Member of the Supervisory Board in January 2023, and he is set to become the Chief Executive Officer in July 2024.
• Alongside this, he will also serve as the Strategic Alliance Officer at the European Organisation for Research and Treatment of Cancer (EORTC) starting February 2024.

Personal Interests and LinkedIn Presence

Beyond his professional achievements, Peters is passionate about mentoring the next generation of leaders and fostering diverse teams. He believes in the power of music to unite people and has been a patron of the Friends of the Berliner Philharmoniker since May 2011. His support for prominent music institutions highlights his well-rounded character and commitment to cultural enrichment.

With 2,427 followers on LinkedIn and a presence on the platform since November 2008, Peters is recognized as a leading voice in his field. His extensive skill set, including expertise in oncology, clinical research, and biopharmaceuticals, underscores his substantial contributions to the industry.

Malte Peters' journey is a testament to his dedication, leadership, and passion for both science and the arts. His career path reflects a commitment to advancing medical research while also advocating for the importance of teamwork and cultural appreciation.